Paradoxical embolization in an adult patient with cystic fibrosis

Mayo Clinic Proceedings

Volumn 75, Issue 10, 2000, Pages 1100-1102

  Espiritu, Joseph D ^a   Kleinhenz, Mary E ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DORNASE ALFA; NEDOCROMIL; PANCREAS ENZYME; SALBUTAMOL; SALMETEROL; WARFARIN; HEPARIN;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; CASE REPORT; CLINICAL FEATURE; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HEART ATRIUM SEPTUM DEFECT; HEMIPARESIS; HUMAN; LUNG DISEASE; NEUROLOGIC DISEASE; RESPIRATORY TRACT INFECTION; RISK FACTOR; SLURRED SPEECH; STROKE; TREATMENT OUTCOME; VASCULAR ACCESS; AFRICAN AMERICAN; ANTICOAGULATION; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; ELECTROENCEPHALOGRAPHY; EMBOLISM; FOLLOW UP; MAGNETIC RESONANCE ANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARADOXICAL EMBOLIZATION; PATENT FORAMEN OVALE; PHYSICAL EXAMINATION; RISK ASSESSMENT; THORAX RADIOGRAPHY;

EID: 0033795609     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/75.10.1100     Document Type: Article

References (10)

1. Davidson A, Chandrasekaran K, Guida L, Holsclaw DS Jr. Enhancement of hypoxemia by atrial shunting in cystic fibrosis. Chest. 1990;98:543-545.
2. Playfor SD, Smyth AR. Paradoxical embolism in a boy with cystic fibrosis and a stroke. Thorax. 1999;54:1139-1140,
3. Meissner I, Whisnant JP, Khandheria BK, et al. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Mayo Clin Proc. 1999;74:862-869.
4. Espiritu JD, Kleinhenz ME. Patent foramen ovale is the most prevalent echocardiographic abnormality in adult cystic fibrosis [abstract] .AmJ Respir Crit Care Med. 2000; 161 :A71.
5. Cystic Fibrosis Foundation Patient Registry, 1997 Annual Data Report. Bethesda, Md: Cystic Fibrosis Foundation; August 1998.
6. Yung B, Campbell IA, Elborn JS, Harvey JS, Shale DJ. Totally implantable venous access devices in adult patients with cystic fibrosis. Respir Med. 1996;90:353-356.
7. Deerojanawong J, Sawyer SM, Fink AM, Stokes KB, Robertson CF, Totally implantable venous access devices in children with cystic fibrosis: incidence and type of complications. Thorax. 1998; 53:285-289.
8. Rodgers HC, Liddle K, Nixon SJ, Innés JA, Greening AP. Totally implantable venous access devices in cystic fibrosis: complications and patients' opinions. Ear Respir J. 1998:12:217-220.
9. Tonelli MR, Aitken ML. Complications of in-dwelling venous catheters in cystic fibrosis: a ten-year review [abstract]. Pediatr Pulmonol Suppl. 1999;19:334. Abstract 589.
10. Van Cott EM, Laposata M. Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am. 1998; 12:1141 -1166.